Format

Send to

Choose Destination
Pathology. 2019 Dec;51(7):673-680. doi: 10.1016/j.pathol.2019.08.006. Epub 2019 Oct 24.

Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer.

Author information

1
Royal North Shore Hospital, St Leonards, and Sydney University, Camperdown, NSW, Australia. Electronic address: nick.pavlakis@sydney.edu.au.
2
Pathology Queensland, Princess Alexandra Hospital, Woolloongabba, Qld, Australia.
3
Olivia Newton-John Cancer Research Institute, Heidelberg, Vic, Australia.
4
Chris O'Brien Lifehouse, Camperdown, NSW, Australia.
5
SA Pathology, and Flinders University at Flinders Medical Centre, Bedford Park, SA, Australia.
6
St George Hospital, Kogarah, NSW, Australia.
7
Austin Health, Heidelberg, Vic, Australia.
8
University of Western Australia, Perth, WA, Australia.
9
Princess Alexandra Hospital, Woolloongabba, Qld, Australia.
10
St Vincent's Hospital, University of Melbourne, Melbourne, Vic, Australia.
11
Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
12
Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; School of Medicine, Western Sydney University, Sydney, NSW, Australia.

Abstract

Lung cancer is the most commonly diagnosed malignancy and the leading cause of death from cancer globally. Diagnosis of advanced non-small cell lung cancer (NSCLC) is associated with 5-year relative survival of 3.2%. ROS proto-oncogene 1 (ROS1) is an oncogenic driver of NSCLC occurring in up to 2% of cases and commonly associated with younger age and a history of never or light smoking. Results of an early trial with the tyrosine kinase inhibitor (TKI) crizotinib that inhibits tumours that harbour ROS1 rearrangements have shown an objective response rate (ORR) of 72% (95% CI 58-83%), median progression free survival (PFS) of 19.3 months (95% CI 15.2-39.1 months) and median overall survival (OS) of 51.4 months (95% CI 29.3 months to not reached). Therefore, with the availability of highly effective ROS1-targeted TKI therapy, upfront molecular testing for ROS1 status alongside EGFR and ALK testing is recommended for all patients with NSCLC. We review the tissue requirements for ROS1 testing by immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) and we present a testing algorithm for advanced NSCLC and consider how the future of pathology testing for ROS1 may evolve.

KEYWORDS:

Non-small cell lung cancer; ROS1; biomarker testing; consensus

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center